Lomibuvir

Research use only, not for human use.

Lomibuvir (VCH-222) is a selective, non-nucleoside allosteric inhibitor of HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC 50 of 5.2 nM.

Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a Kd of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC50 of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis.

Lomibuvir (VX-222) inhibits WT HCV 1b/Con1 replicon with an EC50 of 5.2 nM. Lomibuvir inhibits M423T, L419M and I482L (mutant replicons) with EC50s of 79.8, 563.1, 45.3 nM, respectively. Lomibuvir reduces de novo initiation slightly but also shows strong inhibition of primer extension. The IC50 of Lomibuvir for primer-extended RNA synthesis is 31 nM.Lomibuvir is a non-nucleoside, allosteric inhibitor of the hepatitis C virus NS5B polymerase.

——

——

Others

Other Targets

HCV Protease

——

——

1026785-55-6

445.61

C25H35NO4S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (224.41 mM; Ultrasonic )

CC1CCC(CC1)C(=O)N(C1CCC(O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C

——

(-20℃)

With Ice Pack

≥ 2 years